Treatment for food allergy.

Abstract

The prevalence of IgE-mediated food allergy is an increasing public health concern effecting millions of persons worldwide. The current standard of treatment is strict avoidance of the offending food or foods, and to date, there are no regulatory approved treatments for food allergy. A significant amount of research has been directed at various forms of food immunotherapy, including oral, sublingual, and epicutaneous delivery routes. Although oral immunotherapy has shown the greatest promise for efficacy in terms of the amount of protein that can be ingested, it has also demonstrated less tolerability and a less favorable safety profile compared with sublingual immunotherapy and epicutaneous immunotherapy, which offers the least protection but has the best safety and tolerability profile. Studies have been conducted with adding adjuvants and anti-IgE to enhance either the efficacy or safety of food immunotherapy. Multiple concepts of food immunotherapy beyond these first-generation treatments are in either animal or early phase 1 studies.

• Authors: A Wesley Burks, Hugh A Sampson, Marshall Plaut, Gideon Lack, Cezmi A Akdis
• Journal: The Journal of allergy and clinical immunology (J Allergy Clin Immunol) Vol. 141 Issue 1 Pg. 1-9 (01 2018) ISSN: 1097-6825 [Electronic] United States
• PMID: 29307409 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)
• Copyright: Copyright © 2017 American Academy of Allergy, Asthma & Immunology. All rights reserved.

Chemical References

• Adjuvants, Immunologic

Topics

• Adjuvants, Immunologic (therapeutic use)
• Animals
• Clinical Trials, Phase I as Topic
• Food Hypersensitivity (immunology, pathology, therapy)
• Humans
• Sublingual Immunotherapy